IMA ImageneBio Inc: Indikator likuiditas cepet

This price chart for ImageneBio Inc (IMA) illustrates the dynamics of a company with a coefficient of 21.00. The business remains vulnerable to global conflicts that impact patent law and raw material supplies. Success depends on the results of anti-tumor drug trials and the acquisition of investment. Meanwhile, the brand maintains its status as a reliable creator of innovative methodologies, benefiting from a well-deserved level of trust within the scientific community.

Steady cash flow from operating activities at ImageneBio Inc (IMA) ensures full coverage of current liabilities and capital maintenance. This resilience is confirmed by the trend of the acid-test ratio, which measures the company's ability to settle short-term debts exclusively using cash and accounts receivable, intentionally excluding less liquid inventories from the calculation.